STOCK TITAN
  1. Home
  2. Sec-filings
  3. INAB
  4. [EFFECT] IN8BIO, INC. SEC Filing

[EFFECT] IN8BIO, INC. SEC Filing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
EFFECT

Rhea-AI Filing Summary

Analyzing...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: January 28, 2026 4:00 P.M.
Form: S-3
CIK: 0001740279
Company Name: IN8BIO, INC.
File Number: 333-292830

Source: View Original Filing on SEC EDGAR

In8Bio, Inc.

NASDAQ:INAB

View INAB Stock Overview →

INAB Rankings

#6268 Ranked by Market Cap
N/A Ranked by Dividends

INAB Latest News

Mar 12, 2026
IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026
Feb 24, 2026
IN8bio to Present at TD Cowen 46th Annual Health Care Conference
Feb 9, 2026
IN8bio Promotes Kate Rochlin, Ph.D., to President and Chief Operating Officer
Feb 3, 2026
IN8bio to Present at Upcoming Investor and Scientific Conferences in February
Jan 12, 2026
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma

INAB Latest SEC Filings

Mar 26, 2026
[ARS] IN8BIO, INC. SEC Filing
Mar 26, 2026
[DEF 14A] IN8BIO, INC. Definitive Proxy Statement
Mar 12, 2026
[10-K] IN8BIO, INC. Files Annual Report
Mar 12, 2026
[8-K] IN8BIO, INC. Reports Material Event
Mar 2, 2026
[SCHEDULE 13G] IN8BIO, INC. Passive Investment Disclosure (>5%)

INAB Stock Data

14.48M
7.73M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
NEW YORK